ImmuCell Corporation (ICCC) Announces Earnings Results

ImmuCell Corporation (NASDAQ:ICCC) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. ImmuCell Corporation had a net margin of 4.55% and a return on equity of 2.25%.

ImmuCell Corporation (NASDAQ ICCC) traded up $0.24 on Tuesday, reaching $8.40. The company had a trading volume of 28,700 shares, compared to its average volume of 7,823. ImmuCell Corporation has a one year low of $4.76 and a one year high of $8.83. The company has a current ratio of 1.89, a quick ratio of 1.28 and a debt-to-equity ratio of 0.18. The stock has a market cap of $41.19, a PE ratio of 90.67 and a beta of 1.16.

Separately, ValuEngine upgraded ImmuCell Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th.

TRADEMARK VIOLATION WARNING: “ImmuCell Corporation (ICCC) Announces Earnings Results” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at

About ImmuCell Corporation

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Earnings History for ImmuCell Corporation (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related companies with's FREE daily email newsletter.

Leave a Reply